A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis (Breakfree-1)
Latest Information Update: 22 Jun 2025
At a glance
- Drugs CC-97540 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Acronyms Breakfree-1
- Sponsors Bristol-Myers Squibb; Juno Therapeutics
Most Recent Events
- 06 May 2025 Planned End Date changed from 15 Nov 2027 to 29 Aug 2028.
- 06 May 2025 Planned primary completion date changed from 15 Nov 2027 to 29 Aug 2028.
- 06 Mar 2024 Planned number of patients changed from 43 to 129.